GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review [Yahoo! Finance]
ANI Pharmaceuticals, Inc. (ANIP)
Last ani pharmaceuticals, inc. earnings: 2/27 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
anipharmaceuticals.com/investors_corporate_profile.php
Company Research
Source: Yahoo! Finance
for its investigational, first-in-class oral antibiotic, gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. With the FDA granting a priority review to the NDA, a decision from the regulatory body is expected on March 26, 2025. If approved, gepotidacin could become the first in a new class of oral antibiotic medicines to be approved for treating uUTIs in more than 20 years. Year to date, shares of GSK have increased 5.8% against the industry's decline of 1.8%. Image Source: Zacks Investment Research GSK's NDA Based on Data from Two Phase III Studies The NDA for gepotidacin was based on data from two pivotal phase III studies — EAGLE-2 and EAGLE-3 — which evaluated the safety and efficacy of gepotidacin versus nitrofurantoin, the current standard of care for uUTI. Within the studies, treatment with gepotidacin demonstrated non-inferiority to nitrofurantoin in female adults with confirmed uUTI and a uropathogen suscepti
Show less
Read more
Impact Snapshot
Event Time:
ANIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIP alerts
High impacting ANI Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ANIP
News
- Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $94.00 price target on the stock.MarketBeat
- ANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance [Yahoo! Finance]Yahoo! Finance
ANIP
Earnings
- 11/8/24 - Beat
ANIP
Sec Filings
- 11/20/24 - Form 8-K
- 11/18/24 - Form 4
- 11/18/24 - Form 4
- ANIP's page on the SEC website